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Abstract Between 1981–1999, 75 patients treated for
supraglottic SCC with horizontal supraglottic laryngectomy
(HSL) at the Otolaryngology Head and Neck Surgery De-
partment of Lausanne University Hospital were retrospec-
tively studied. There were 16 patients with T1, 46 with T2
and 13 with T3 tumors. Among these, 16 patients (21%)
had clinical neck disease corresponding to stage I, II, III
and IV in 12, 39, 18 and 6 patients, respectively. All pa-
tients had HSL. Most patients had either elective or thera-
peutic bilateral level II–IV selective neck dissection. Six
patients (8%) with advanced neck disease had ipsilateral
radical and controlateral elective II–IV selective neck dis-
sections. Adjuvant radiotherapy was given to 25 patients
(30%) for either positive surgical margins (n=8), patho-
logical nodal status (n=14) or both (n=3). Median follow-
up was 48 months (range, 24–199). Five-year disease-spe-
cific survival and locoregional and local control were 92,
90 and 92.5%, respectively. Among five patients who
were diagnosed with local recurrence, one had a total la-
ryngectomy (1.4%); the others were treated by endoscopic
laser surgery. Two patients had both a local and regional
recurrence. They were salvaged with combined surgery
and radiotherapy, but eventually died of their disease.
Cartilage infiltration seems to influence both local control
(P=0.03) and disease-specific survival (P=0.06). There
was a trend for worse survival with pathological node in-
volvement (P=0.15) and extralaryngeal extension of the
cancer (P=0.1). All patients except one recovered a close
to normal function after the treatment. Aspiration was
present in 16 patients (26%) in the early postoperative pe-
riod. A median of 16 days (7–9) was necessary to recover
a close to normal diet. Decannulation took a median of 
17 days (8–93). Seven patients kept a tracheotomy tube
for up to 3 months because of persistent aspiration. There
was no permanent tracheostomy or total laryngectomy for
functional purposes. Horizontal supraglottic laryngec-
tomy remains an adequate therapeutic alternative for supra-
glottic squamous cell carcinoma, offering an excellent on-
cological outcome. The postoperative functional morbid-
ity is substantial, indicating the need for careful patient
selection, but good laryngeal function recovery is the rule.
The surgical alternative is endoscopic laser surgery, which
may offer comparable oncological results with less func-
tional morbidity. Nevertheless, these two different tech-
niques need to be compared prospectively.
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Introduction
There is no real consensus on the best treatment option for
supraglottic squamous cell carcinoma. Single modalities
using either surgery or radiotherapy alone or combined se-
quential therapy are different therapeutic options available
[1, 2]. In 1947, Alonso [3] described horizontal partial la-
ryngectomy (HPL) as a surgical treatment for supraglottic
squamous cell carcinoma. This technique took several decades
to gain widespread recognition, but, in the past 20 years, it
has progressively replaced total laryngectomy for selected
cancers. Radiation therapy is a recognized alternative treat-
ment allowing preservation of laryngeal function. Pro-
vided patients are carefully selected, both treatments ap-
pear to offer comparable oncological and functional out-
comes [4, 5, 6, 7].
In our department, functional laryngeal surgery has been
the main line of treatment for selected glottic and supra-
glottic SCC for 20 years [8, 9]. We have usually kept en-
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doscopic treatment as an alternative treatment to radio-
therapy for early glottic cancers [10]. HPL, as described
by Alonso [3], was mostly used for healthy patients pre-
senting with stage II and above SCCs of the supraglottis.
Advanced chronic respiratory disease was considered a
contraindication. Thus, radiotherapy was kept as an adju-
vant treatment or as a primary treatment modality for
those patients medically unfit for functional laryngeal sur-
gery still trying to avoid the morbidity of total laryngec-
tomy.
Progressively introduced in the last 10 years, transoral
CO2 laser excision combined with surgery and/or radio-
therapy to the neck seems to offer a valuable surgical al-
ternative for the treatment of supraglottic primaries, with
a more rapid recovery of laryngeal function [11, 12, 13].
We have recently introduced this technique in our depart-
ment and are currently studying our results prospectively.
During the past 18 years, our standard approach has been
an open horizontal partial laryngectomy. This retrospective
study of 75 patients analyzes the postoperative course, mor-
tality and morbidity of this surgical approach to supraglot-
tic cancer.
Subjects and methods
During the period of 1981 to 1999, 75 supraglottic partial laryn-
gectomies were performed in the department of Otolaryngology
and Head and Neck Surgery of Lausanne University Hospital. All
clinical and pathological data were reviewed retrospectively.
Among the 75 patients, there were 70 male and 5 female patients
with a median age of 58 years (range, 32–75). The staging accord-
ing to the 1983 American Joint Committee on Cancer Staging
(AJCCS) is listed in Table 1.
Follow-up data were collected through bimonthly visits in our
department for the first 2 years, extended to twice a year for the
following years. Median follow-up was 48 months (range, 24–
199). All patients presented with supraglottic squamous cell carci-
noma. The tumor was confined to the laryngeal surface of the
epiglottis extending into the larynx and the valleculae or tongue
base in 68 (91%) and 7 (9%) patients, respectively. Patients with
lateral extension to the pharynx were excluded. One patient had
been treated previously with radiotherapy for a SCC of the epiglot-
tis.
All patients had a pretherapeutic panendoscopy, including rigid
broncho-esophagoscopy and direct laryngoscopy, to determine the
extent of the tumor accurately and define the indication for sur-
gery. Surgical treatment included HPL, along with bilateral neck
dissection. The pharynx was systematically open at the tongue
base to locate the anterior commissure and resect the thyroid carti-
lage precisely above the glottis, along with the entire epiglottis and
the preepiglottic space. A pexy was then performed between the
tongue base and the lower third of the thyroid cartilage. Our indi-
cation for this surgery was cancer of the supraglottis without ex-
tension into the vocal cords and minimal extension into the tongue
base. The extent of neck surgery was dependent on the clinical sta-
tus of the neck nodes, but all patients had at least a bilateral selec-
tive neck dissection, preserving the submandibular triangle, inter-
nal jugular vein, sternocleidomastoid muscle and spinal accessory
nerve. Indication for adjuvant radiotherapy was as follows: posi-
tive or insufficient surgical margins and multiple neck nodes or ex-
tracapsular spread. If needed, radiotherapy courses were scheduled
within 6 weeks postoperatively and delivered weekly over a period
of 6 to 10 weeks to reach a total dose of 45–60 Gy. No patient had
clinically positive neck disease treated with radiotherapy alone.
Statistical analysis was performed with JMP Statistics Made
Visual software (SAS Institute Inc., Trunbull, Conn.). Means were
compared by Student’s t-test. Proportions were compared using a
chi-square test for values greater than five and the Fisher’s exact
test for those less than or equal to five. Kaplan-Meier product-limit
estimates were used to evaluate overall survival, cause-specific
survival and local control in both groups. Univariate analysis of
correlation of the following independent factors – age, tumor ex-
tension and pre- versus postoperative nodal disease – to local con-
trol and cause-specific survival was performed using the log-rank
test. Multivariate analyses were done using the Cox stepwise re-
gression analysis to determine the independent contribution of
each prognostic factor.
Results
There were 16 (21%) therapeutic and 59 (79%) elective neck
dissections. There were 69 bilateral selective level II–IV
neck dissections, preserving the internal jugular vein, the
spinal accessory nerve, the sternocleidomastoid muscle
and the submandibular triangle. Six patients (8%) with
clinically advanced disease (N3) had an ipsilateral radical
neck dissection and a contralateral, selective, level II–IV
dissection. The submandibular triangle was dissected on
the ipsilateral side in two patients who initially presented
with an oral second primary, which was treated surgically,
at the same time.
Histopathology showed close or involved surgical mar-
gins in 16 patients (21%). Overall, 26 patients had patho-
logically positive lymph nodes (35%); of these, ten cases
(15%) were occult nodal disease. Pathological staging is
listed in Table 2. Adjuvant radiotherapy was indicated in
25 patients, by nodal status in 14 cases, positive surgical
margins in 8 and both in 3.
Minor postoperative complications such as hematomas
and neck infections affected four and two patients, respec-
tively. Two patients presented a dehiscent pexy in the im-
mediate postoperative period, which was diagnosed and
immediately treated surgically without long-term conse-
quences for the patients. Other medical complications in-
cluded one pulmonary embolism, one deep venous throm-
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Table 1 Distribution by clinical T and N stage
T1 T2 T3
N0 12 36 11 59
N1 0 3 1 4
N2 1 5 0 6
N3 3 2 1 6
Total 16 46 13 75
Table 2 Distribution by pathological T and N stage
pT1 pT2 pT3 pT4
pN0 12 28 7 2 49
pN1 1 6 4 0 11
pN2 0 8 2 0 10
pN3 3 1 0 1 5
Total 16 43 13 3 75
bosis and two pneumonias. They could all be managed
during hospitalization. No patient died during the postop-
erative period.
The overall 5-year local and locoregional control rate
was 92.5 and 90%, respectively. Local recurrence only was
the cause of failure in three patients. Two of them were
salvaged surgically, retaining their larynx. One had a total
laryngectomy for a deep recurrence in the tongue base.
Another two patients had both a local and regional failure.
They were treated with combined surgery and radiation
therapy. One patient was salvaged, but the second died of
his disease. Neck recurrence alone occurred in three pa-
tients. Salvage treatment was surgical and successful in
one of them. Globally, five of eight locoregional recur-
rences were salvaged successfully. The ultimate 5-year lo-
coregional control was then 95% with a 98.5% laryngeal
preservation rate. With 100% 5-year local control for pT1,
91% for pT2, 92 and 66% for pT3 and pT4, respectively,
pathological T-stage did not appear to influence signifi-
cantly local control for pT1–pT3 tumors. Probably due to
the small number of recurrences encountered, infiltration
of the larynx skeleton (pT4 vs. pT1–3) was the only vari-
able showing an impact on local control (P<0.03) (Table 3).
Distant spread of disease was the cause of failure in six
patients. Distant metastasis involved the liver, lung and
bone. The overall 5-year incidence of distant metastasis
was 6.9%.
On initial panendoscopy, four patients (5%) were diag-
nosed with early stage synchronous second primary can-
cers in the oral cavity, the larynx and the lung. During reg-
ular follow-up, 17 (23%) metachronous cancers were di-
agnosed. They involved the upper aerodigestive tract,
lung and esophagus in nine, seven and one patients, re-
spectively. The median time of detection of these second
primaries was 71 months (range 4–200). Treatment was
surgical in all cases, except for the esophageal second pri-
mary, which was diagnosed at a very early stage and was
successfully treated with endoscopic photodynamic ther-
apy. Of those 17 patients, 9 died from their second cancer.
The 5-year overall and cause-specific actuarial survival
rates were 75 and 92%, respectively. Causes of death are
summarized in Table 4. Survival appeared not to be influ-
enced by the size of the primary. Disease-specific survival
by pathological T-stage was 93, 91, 100 and 66% for pT1,
pT2, pT3 and pT4, respectively. Extension of the cancer
into the cartilaginous framework of the larynx, however,
seems to have an influence, but did not reach statistical
significance. There was also a trend for worse survival
when the primary cancer extends into the oropharynx and
when neck nodes are involved. Because of the relatively
small number of cases, none of these variables reached
statistical significance (Table 3).
Postoperatively, the median time for decannulation
was 17 days (range 8–93). For 16 patients (21%), aspira-
tion delayed closure of the tracheotomy. Of those, seven
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Table 3 Univariate analysis in
75 patients for local control
and disease-free survival
n Five years local control Five years disease-free survival
% P value % P value
All patients 75 92.5 92.0
Age
<60 years 43 92.5 NS 92.5 NS
>60 years 32 92.4 91.2
Primary site
Extralaryngeal 7 83.3 NS 85.7 0.10
Endolaryngeal 68 93.3 92.6
Cartilage infiltration
Yes 3 66.6 0.03 66.6 0.06
No 72 93.6 93.1
Surgical resection margin
Positive 16 93.7 NS 91.6 NS
Negative 59 92.5 92.1
Pathological N-status
pN + 26 – – 86.6 0.15
pN 0 49 – – 95.0
Postoperative radiation
Yes 25 95.8 NS 94.8 0.15
No 50 90.6 86.6
Table 4 Causes of death
Cause of death No. of %
patients
TNM related death
Local recurrence 1 1
Neck recurrence 2 2
Metastasis 4 5
Second primary tumor 9 12
Other cancer 2 3
Intercurrent disease 18 24
patients (9%) were discharged with a tracheotomy and a
nasogastric feeding tube. All of them were eventually de-
cannulated and able to swallow in a maximum period of 
3 months, providing intensive swallowing rehabilitation.
One patient became aphagic after radiotherapy because of
cricopharyngeal muscle stenosis. He then needed inser-
tion of a percutaneous gastrostomy and has not been able
to eat since, even after multiple endoscopic dilatations.
There was no total laryngectomy for failure to recover
function.
Discussion
Optimal management of supraglottic cancers aiming at
the best possible cure and functional conservation has
been a matter of debate between surgeons and radiation
oncologists for many years. We have reviewed a series of
75 patients with supraglottic SCC treated primarily with
HPL.
Cancers of the supraglottis are efficiently treated with
functional surgery, which achieves a very good local con-
trol of the disease in early lesions. But, more advanced
primaries are less likely to be treated by surgery alone, no-
tably when the tumor extends into the base of the tongue,
laryngeal cartilages or paralaryngeal spaces [4, 5, 14]. For
stage I and II diseases, both Bocca et al. [4] and DeSanto
[5] report between 85–100% local control at 3 years after
treatment with HPL in series of 537 and 70 patients, re-
spectively. Advanced stage of disease is usually accompa-
nied with a drop in local control, in particular for T4 can-
cers [4, 15]. Most of the recurrences present in the tongue
base, but salvage treatment is efficient, even if it often re-
quires a total laryngectomy. Adjuvant radiotherapy improves
both local control and survival in cases with advanced
neck disease or positive surgical margin and is therefore
considered standard in these settings [14, 16].
With primary radiotherapy more so than surgery, recur-
rence rates are dependent on the primary tumor volume
and the degree of pre-epiglottic space infiltration, as seen
on CT examination [17]. Local control varies greatly with
stage between 100 to 27% from T1 to T4 cancers, respec-
tively [7, 18]. In case of recurrence, surgical salvage is ef-
ficient, but requires a total laryngectomy in up to 30% of
cases, even for patients initially eligible for a functional
procedure [7, 18, 19]. Failure in the neck is a significant
problem in supraglottic cancer and impacts on patient sur-
vival [2, 6, 15, 16]. Whereas positive neck nodes require
combined surgery and radiotherapy [7, 16], the manage-
ment of the clinically negative neck at present is still con-
troversial.
The percentage of occult nodal disease is around 30%
[5, 6, 20]. Unilateral treatment, based on the initial local-
ization of the primary, is insufficient and carries a high
risk of failure in the contralateral neck [5, 6, 15]. Bilateral
irradiation appears effective in eradicating occult metasta-
sis in both sides of the neck, but carries significantly more
long-term morbidity than elective surgical treatment [5,
6]. It therefore has been our attitude to perform systemat-
ically bilateral anterior (level II–IV) neck dissection as
both a therapeutic and diagnostic measure and to use com-
bined therapy, with adjuvant radiotherapy, when neces-
sary. Our findings of 35% pathological neck disease and
our extremely low rate of regional recurrence (8%) sup-
port our practice. Despite the relatively low percentage of
occult nodal disease (15%) in our series, we preferred bi-
lateral selective neck dissection, preserving the submandibu-
lar triangle, internal jugular vein, sternocleidomastoid
muscle and spinal accessory as it carries hardly no mor-
bidity compared to a bilateral prophylactic irradiation.
Using primary surgery and adjuvant radiotherapy, our
global 5-year local control rate was 92.5%. With 100, 91,
92 and 66% for T1, T2, T3 and T4, respectively, our re-
sults compare favorably with previously published data
[4, 5, 14, 15]. Among eight patients who recurred, three
failed at the primary site only. They could all be salvaged,
with one patient losing his larynx. The other five patients
failed in the neck. Combined surgery and radiotherapy
salvaged two patients, but three could not be controlled
and eventually died of their disease. Our 5-year overall
loco-regional control was then 95% with a 98.5 laryngeal
conservation rate.
Despite our good 92% disease-free survival rate at 
5 years, the overall 5-year survival was 75%, mainly be-
cause of second primary cancers. Mostly found in the lung,
they are diagnosed on routine follow-up radiological ex-
amination and often confirmed endoscopically. The high
incidence of metachronous cancers is a recognized prob-
lem of head and neck cancers, especially in survivors of
laryngeal cancers [9, 21]. Despite systematic pretherapeu-
tic broncho-esophagoscopy, regular postoperative follow-
up and broncho-esophageal cytological studies with con-
trol panendosocopies at 2 years, patients appeared to pre-
sent with aggressive second primaries in the lung, which
are often fatal [22]. In addition, with such a high loco-
regional control rate, distant metastases are beginning to
have a significant impact on survival, a phenomenon that
we have previously noticed in glottic cancers [9]. Some
authors advocate the use of neoadjuvant chemotherapy
before surgery for laryngeal cancers. Thus, they intend to
control some of the early tumoral dissemination and ef-
fectively achieve better survival [23].
Our functional results were satisfactory. Normal laryn-
geal function, with removal of the tracheostomy tube and
a close to normal diet, was reached in 80% of the patients
within a month. Recovery of a good swallowing function
was delayed in 16 patients. However, they were all de-
cannulated and able to eat in the first 3 months after the
surgery. No completion laryngectomy for intractable aspi-
ration was needed. With 98.5%, our overall laryngeal
preservation rate compares favorably with previously
published data reporting 98 to 93% laryngeal preservation
rates after surgery [14, 24] and 84% after radiotherapy
[18]. Recovering a close to normal swallowing function
after HPL is often a major problem, and an increased in-
cidence of life-long gastrostomy has been reported [25,
26]. In our series, only one patient, who presented with
cricopharyngeal muscle stenosis after adjuvant radiother-
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apy, required a percutaneous gastrostomy and never re-
covered normal swallowing, despite multiple attempts at
endoscopic dilatation. However, open surgery of the lar-
ynx remains a serious undertaking for some patients whose
general health condition, notably respiratory, may not al-
low the transient postoperative loss of laryngeal function.
Conclusion
With careful selection of the patients, HPL, along with ad-
juvant radiotherapy, is a suitable treatment option for supra-
glottic SCC. Postoperative recovery of laryngeal function
is the rule, and long-term sequelae are infrequent, with
60% of the patients avoiding adjuvant treatment. For the
initial early stage of the disease (stages I–II), radiotherapy
seems to offer a similar outcome with less immediate
functional morbidity. However, in patients initially suit-
able for functional surgery, salvage of local failure most
often requires a total laryngectomy. Based on these re-
sults, our first line of treatment for surpaglottic cancers
remains surgical.
Transoral CO2 laser resection of these cancers controls
early stages of the disease with efficiency comparable to
open surgery and carries less laryngeal morbidity. This
fairly new approach has brought promising results and of-
fers an excellent alternative treatment for selected pa-
tients. Following the publication of numerous convincing
reports, we have recently introduced transoral CO2 laser
resections in our department and are prospectively collect-
ing data to compare endoscopic with open transcervical
horizontal partial laryngectomies
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